Expert Review of Vaccines最新文献_第9页

Impact of prior COVID-19 vaccination on major adverse kidney events in patients with non-dialysis dependent chronic kidney disease: a global retrospective study. 先前接种COVID-19疫苗对非透析依赖型慢性肾病患者主要肾脏不良事件的影响：一项全球回顾性研究

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-22 DOI: 10.1080/14760584.2025.2536077

Chi-Ya Huang, Jheng-Yan Wu, Guan-Yu Lin, Shin-Jhe He, Hsien-Yi Wang, Ming-Cheng Wang, Tsung Yu, Ming-Chuan Hung, Chih-Cheng Lai, I-Ning Yang

{"title":"Impact of prior COVID-19 vaccination on major adverse kidney events in patients with non-dialysis dependent chronic kidney disease: a global retrospective study.","authors":"Chi-Ya Huang, Jheng-Yan Wu, Guan-Yu Lin, Shin-Jhe He, Hsien-Yi Wang, Ming-Cheng Wang, Tsung Yu, Ming-Chuan Hung, Chih-Cheng Lai, I-Ning Yang","doi":"10.1080/14760584.2025.2536077","DOIUrl":"10.1080/14760584.2025.2536077","url":null,"abstract":"Background: Vaccination prevents complications and death in patients with chronic kidney disease (CKD) and COVID-19, but concerns remain about post-vaccination kidney outcomes. This study assessed the real-world impact of prior COVID-19 vaccination on major adverse kidney events (MAKEs) in CKD patients with COVID-19.Research design and methods: We conducted a global retrospective cohort study using the TriNetX database from 1 January 2020, to 31 May 2024. Propensity score matching created a 1:1 cohort of 8,520 vaccinated and 8,520 unvaccinated CKD patients with COVID-19. Outcomes included MAKEs and all-cause mortality within 30 days. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Subgroup and sensitivity analyses were performed.Results: The vaccinated group had significantly lower risks of MAKEs or mortality (HR: 0.637; 95% CI: 0.581-0.689), MAKEs (HR: 0.792; 95% CI: 0.698-0.898), and mortality (HR: 0.549; 95% CI: 0.484-0.622). More outcome benefits were seen in those with ≥ 3 vaccine doses. Sensitivity analyses confirmed these findings.Conclusions: In CKD patients with COVID-19, prior vaccination significantly reduced risks of MAKEs and mortality, especially with three or more doses. These findings underscore the clinical importance of adhering to recommended vaccination schedules to improve kidney outcomes and survival in this vulnerable population.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"657-666"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis. 中国9-16岁女孩接种人乳头瘤病毒疫苗的成本效益：一项荟萃分析

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-13 DOI: 10.1080/14760584.2025.2517715

Xiaoya Fu, Yilan Xia, Weiyu Zhou, Yihan Lu

{"title":"Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis.","authors":"Xiaoya Fu, Yilan Xia, Weiyu Zhou, Yihan Lu","doi":"10.1080/14760584.2025.2517715","DOIUrl":"10.1080/14760584.2025.2517715","url":null,"abstract":"Introduction: Imported 2 v, 4 v, and 9vHPV vaccines are costly in China, whereas the domestic 2vHPV is more affordable. This study aimed to summarize cost-effectiveness evidence by pooling the incremental net monetary benefit (INB) of HPV vaccination for girls in China.Methods: We searched PubMed, Embase®, Web of Science, and Cochrane databases from inception to 18 January 2024, for cost-effectiveness analyses of 2vHPV, 4vHPV, and 9vHPV vaccines compared to no HPV vaccination (NoV) and to each other. All monetary units were adjusted to 2022 US dollars. INBs were calculated as the difference in incremental effectiveness multiplied by the willingness-to-pay threshold minus the incremental cost and pooled by vaccine type using random-effects or fixed-effects models.Results: Sixteen studies involving 61 comparisons were included. The INBs (95% CI) for domestic 2vHPV, imported 2vHPV, 4vHPV, and 9vHPV vaccines, compared to NoV, were USD 569.99 (58.62, 1081.36), 186.39 (86.21, 286.57), 239.14 (142.46, 335.81), and 298.41 (198.31, 398.51), respectively. HPV vaccines were significantly cost-effective compared to NoV. 4vHPV vaccine was less cost-effective than imported 2vHPV vaccine, with an INB of USD - 693.98 (-1062.17, -325.79).Conclusions: HPV vaccines were cost-effective compared to NoV in China. Our findings would facilitate policy-making of HPV immunization programs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"524-534"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009-2019. 2009-2019年深圳住院儿童肺炎链球菌血清型分布及非药敏性变化

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-14 DOI: 10.1080/14760584.2025.2531898

Feiling Wang, Xiaojing Zeng, Qianqian Du, Yingqi Deng, Jing Peng, Rui Dong, Wenyan Hu, Hongbo Xie, Wei Shi, Haitao Chen, Ping Jin, Kaihu Yao, Lijuan Wu

{"title":"Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009-2019.","authors":"Feiling Wang, Xiaojing Zeng, Qianqian Du, Yingqi Deng, Jing Peng, Rui Dong, Wenyan Hu, Hongbo Xie, Wei Shi, Haitao Chen, Ping Jin, Kaihu Yao, Lijuan Wu","doi":"10.1080/14760584.2025.2531898","DOIUrl":"10.1080/14760584.2025.2531898","url":null,"abstract":"Background: This study assessed changes in Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility among hospitalized children with pneumonia in Shenzhen, China, from 2009 to 2019, under low pneumococcal conjugate vaccine (PCV) coverage.Research design and methods: We analyzed 1,361 isolates (62 invasive, 1,299 noninvasive). Serotypes were identified by latex agglutination and Quellung reaction. Antimicrobial susceptibility was determined using E-test, and vaccination data were obtained from the local CDC.Results: PCV13 serotype coverage remained high among invasive isolates (96.8%) and represented a substantial proportion of all isolates. A marked decline in serotype 19F (from 59.2% to 14.4%) and increased serotype diversity (from 14 to 26 types) were observed. Non-susceptible rates to four beta-lactam antibiotics decreased from 16.0% to 2.4%, largely due to the decline of serotype 19F. PCV vaccination rates rose to 31.1% by 2019. Non-vaccine serotypes increased over time, with some (e.g. 15B/C) showing elevated beta-lactam MICs.Conclusions: Despite low vaccination rate, PCV13 serotypes remained predominant among isolates. The decline of serotype 19F and reduced beta-lactam nonsusceptibility suggest vaccine impact. Rising serotype diversity and the emergence of nonsusceptible non-vaccine types highlight the need for continued surveillance.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"624-634"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule. 采用2 + 1接种计划的15价和20价肺炎球菌结合疫苗对儿童免疫原性的间接比较

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-09-30 DOI: 10.1080/14760584.2025.2569037

Shahrul Mt-Isa, Justin R Chumbley, Matthew S Kelly, Jessica Weaver, Natalie Banniettis

{"title":"Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule.","authors":"Shahrul Mt-Isa, Justin R Chumbley, Matthew S Kelly, Jessica Weaver, Natalie Banniettis","doi":"10.1080/14760584.2025.2569037","DOIUrl":"https://doi.org/10.1080/14760584.2025.2569037","url":null,"abstract":"Background: Clinical trials have compared new pneumococcal conjugative vaccines (PCVs; PCV15 and PCV20) to an established PCV (PCV13) in a routine 2 + 1 schedule. This study performed an indirect comparison of PCV15 vs. PCV20 immune responses in healthy infants and toddlers.Research design and methods: Pooled, matching-adjusted PCV15 trials were indirectly compared to the analogous PCV20 trial for IgG response rate difference (RRD) and geometric mean concentration ratio (GMR) at the post-primary series (PPS) and post-toddler dose (PTD) timepoints.Results: At PPS, PCV15 was non-inferior for RRD and GMR as compared to PCV20 for all PCV13 serotypes. Moreover, PCV15 was superior to PCV20 for the RRDs of serotypes 1, 3, 4, 5, 6B, 9 V, and 23F and GMRs of serotypes 3, 4, 5, 6B, 9 V, and 23F at PPS. At PTD, RRDs were comparable for all PCV13 serotypes, except serotype 3, for which PCV15 was superior. PCV15 was superior for the GMRs of serotypes 3, 6B, and 23F, and comparable for the remaining serotypes at PTD. RRDs for serotypes 22F and 33F were non-inferior at both PPS and PTD.Conclusion: In a 2 + 1 schedule, PCV15 demonstrates immunogenicity comparable or superior to PCV20 across PCV13 serotypes, especially for serotype 3.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study. 尼西米单抗对中国婴儿呼吸道合胞病毒相关急性下呼吸道感染的公共卫生影响：一项模拟研究

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-07-17 DOI: 10.1080/14760584.2025.2526601

Xiaozhen Lai, Yidi Ma, Weishun Zou, Samira Soudani, Hai Fang

{"title":"Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study.","authors":"Xiaozhen Lai, Yidi Ma, Weishun Zou, Samira Soudani, Hai Fang","doi":"10.1080/14760584.2025.2526601","DOIUrl":"https://doi.org/10.1080/14760584.2025.2526601","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) causes substantial acute lower respiratory infections (ALRI), particularly during infants' first RSV season. This study evaluated the impact of a new long-acting monoclonal antibody, nirsevimab, on Chinese infants.Research design and methods: A monthly decision-analytic model assessed nirsevimab's impact for the 2024 birth cohort, incorporating domestic RSV-ALRI parameters. Outcomes included RSV-ALRI cases, hospitalization involving intensive care unit admission and mechanical ventilators use, in-hospital deaths and quality-adjusted life years (QALYs).Results: Without intervention, a total of 873 035 RSV-ALRI cases (269 067 hospitalized), 2 125 deaths, 74 422 QALY loss and $998 million costs were estimated, where higher-risk infants (5.23% of the cohort) accounted for 8.83% of inpatient cases, 12.23% of deaths and 9.87% of costs. With 20% coverage for higher-risk and 10% for healthy term infants, nirsevimab could prevent 61 094 RSV-ALRI cases (19 905 hospitalized), 168 deaths and 5 808 QALY loss, saving $77 million. Tripling the coverage could avert 183 282 RSV-ALRI cases (59 713 hospitalized), 506 deaths and 17 425 QALY loss, saving $231 million.Conclusions: Nirsevimab introduction could effectively mitigate RSV-ALRI burden in Chinese infants, and enhanced coverage is recommended to maximize the public health benefits.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccination policies for dentists and other dental professionals in Europe: a systematic report. 欧洲牙医和其他牙科专业人员的疫苗接种政策：一份系统报告。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-06-05 DOI: 10.1080/14760584.2025.2516254

Helena C Maltezou, Audrey Camilleri, Nuala Carney, Anna Chainier, Katrín Guðmundsdóttir, Erminija Guzaitienė, Charlotte Heuzé, Jörg Krainhöfner, Peter Kukolik, Mercedes Linninger, Jens Nagaba, Miguel Pavao, Harry-Sam Selikowitz, Nikolai Sharkov, Freddie Sloth-Lisbjerg, Roman Smucler, Marek Szewczyński, Brigitte van Dam, Luca Vettore, Lynn Woods, Oliver Zeyer, Ioannis Tzoutzas

{"title":"Vaccination policies for dentists and other dental professionals in Europe: a systematic report.","authors":"Helena C Maltezou, Audrey Camilleri, Nuala Carney, Anna Chainier, Katrín Guðmundsdóttir, Erminija Guzaitienė, Charlotte Heuzé, Jörg Krainhöfner, Peter Kukolik, Mercedes Linninger, Jens Nagaba, Miguel Pavao, Harry-Sam Selikowitz, Nikolai Sharkov, Freddie Sloth-Lisbjerg, Roman Smucler, Marek Szewczyński, Brigitte van Dam, Luca Vettore, Lynn Woods, Oliver Zeyer, Ioannis Tzoutzas","doi":"10.1080/14760584.2025.2516254","DOIUrl":"https://doi.org/10.1080/14760584.2025.2516254","url":null,"abstract":"Background: Dentists and other dental healthcare professionals (DHCP) are at increased risk for several vaccine-preventable diseases (VPDs). We studied vaccination policies for DHCP in Europe.Methods: The national dental associations and chambers of 31 European countries were invited to complete a structured form. The survey was conducted in 2023.Results: Vaccination policies for DHCP existed in all (21) participating countries. Vaccination policies against hepatitis B, COVID-19 and influenza existed in 20, 18, and 17 countries, respectively. Vaccination policies against measles, mumps, rubella, and varicella existed in 8, 7, 7, and 7 countries, respectively, and against diphtheria, tetanus, poliomyelitis, and pertussis in 5, 5, 4, and 2 countries, respectively. Vaccination policies against hepatitis A existed in 5 countries, against meningococcus C, meningococcus A, C, W, Y, and meningococcus B in 1, 2, and 2 countries, respectively, and against tuberculosis and pneumococcus in 4 countries each. Thirteen countries had mandatory vaccination policies.Conclusions: All participating countries had vaccination policies targeting DHCP, however there were significant differences in the number of vaccinations and the implementation frame (mandatory or voluntary vaccinations). Considering the recent outbreaks of VPDs in Europe, vaccination programs for DHCP should be evaluated and strengthened to promote safety in dental facilities.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary of responses to common misconceptions relating to updated COVID-19 mRNA vaccines. 对与更新的COVID-19 mRNA疫苗有关的常见误解的反应的简明语言总结。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-04-04 Epub Date: 2025-04-10 DOI: 10.1080/14760584.2025.2480300

George Kassianos, Ivan Aloysius

引用次数: 0

A plain language summary of the available safety data for the BNT162b2 COVID-19 vaccine: development, approval, and surveillance of use. BNT162b2 COVID-19疫苗现有安全性数据的简明语言摘要：开发、批准和使用监测。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-04-04 DOI: 10.1080/14760584.2025.2480282

Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Claudia Lindemann, Federico Mensa

引用次数: 0

Estimating the time required to reach HPV vaccination targets across Europe. 估算欧洲实现 HPV 疫苗接种目标所需的时间。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-09-13 DOI: 10.1080/14760584.2024.2402535

Ilias Gountas,Mohammed Aman,Deepak Alexander,Robert Hughes,Georgie Weston,Ugne Sabale

{"title":"Estimating the time required to reach HPV vaccination targets across Europe.","authors":"Ilias Gountas,Mohammed Aman,Deepak Alexander,Robert Hughes,Georgie Weston,Ugne Sabale","doi":"10.1080/14760584.2024.2402535","DOIUrl":"https://doi.org/10.1080/14760584.2024.2402535","url":null,"abstract":"BACKGROUNDCervical cancer (CC) is one of the most common causes of cancer-related deaths in women. The World Health Organization (WHO) has called for the CC elimination as a public health priority and has urged countries to achieve a 90% vaccine coverage rate of human papilloma virus (HPV) vaccination among 15-year-old girls by 2030.RESEARCH DESIGN AND METHODSRegression models were fitted to the WHO HPV vaccine coverage rate data to estimate when the 90% vaccine coverage rate target would be achieved in 22 European countries.RESULTSThe mean vaccine coverage rate of included countries was 62.2% (SD: 18.3). Nine countries (Iceland, Norway, Portugal, Ireland, Hungary, Spain, Sweden, Denmark, and Switzerland) are expected to achieve a 90% vaccine coverage rate by 2030. Six countries (Estonia, Cyprus, Netherlands, France, Germany, and Italy) are expected to reach a 90% vaccine coverage rate between 2030 and 2040 whereas seven countries (Belgium, Bulgaria, Finland, Latvia, Luxembourg, Malta, and Slovenia) are not expected to achieve the 90% vaccine coverage rate target by 2040.CONCLUSIONThe majority of European countries are not on track to achieve 90% vaccine coverage rate by 2030. To achieve this, a significant increase in the annual vaccine coverage rate growth rate is required.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"21 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. 关于 Moderna, inc.COVID-19 疫苗的实际影响的描述性综述。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-09-13 DOI: 10.1080/14760584.2024.2402955

Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi

{"title":"A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines.","authors":"Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi","doi":"10.1080/14760584.2024.2402955","DOIUrl":"https://doi.org/10.1080/14760584.2024.2402955","url":null,"abstract":"INTRODUCTIONSince the original COVID-19 vaccines were developed, abundant clinical trial and real-world evidence evaluating the efficacy, effectiveness, and safety of COVID-19 vaccines has been collected. Knowledge of the relative benefits and risks of COVID-19 vaccines is essential for building trust within target populations, ensuring they remain effectively and safely protected against an enduring infectious threat.AREAS COVEREDThis descriptive review discusses the benefits and risks associated with marketed Moderna, Inc. mRNA-based COVID-19 vaccines, focusing on their real-world effectiveness and safety profiles in various age groups. Adverse events of interest and potential benefits of vaccination are reviewed, including reduced risk for severe COVID-19 and long-term health outcomes, reduced economic and societal costs, and reduced risk for SARS-CoV-2 transmission.EXPERT OPINIONPost-marketing safety and real-world data for Moderna, Inc. COVID-19 mRNA vaccines strongly support a positive benefit - risk profile favoring vaccination across all age groups. Although COVID-19 is no longer considered a global health pandemic, health risks associated with SARS-CoV-2 infection remain high. Concerted efforts are required to engage communities and maintain protection through vaccination. Continued surveillance of emerging variants and monitoring of vaccine safety and effectiveness are crucial for ensuring sustained protection against SARS-CoV-2.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"81 5 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0